Summary & Overview
HCPCS A9609: Fludeoxyglucose F18 Supply, up to 15 mCi
HCPCS Level II code A9609 represents the supply of fludeoxyglucose F18 (FDG) up to 15 millicuries for positron emission tomography (PET) imaging. As a radiopharmaceutical supply code, A9609 is a discrete billable item that affects imaging cost structure, facility billing workflows, and payer coverage determinations. Nationally, FDG PET remains a widely used diagnostic tool across oncology, neurology, and cardiology, making supply codes like A9609 relevant for utilization and policy discussions.
Key payers addressed in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise review of how A9609 is classified and billed, benchmarks for typical use cases, and the clinical context in which up to 15 mCi doses are administered. The publication summarizes coverage patterns and common billing considerations, highlights where policy updates may influence reimbursement, and outlines practical implications for imaging sites and hospital outpatient departments.
This executive summary prepares clinical managers, revenue cycle staff, and policy analysts to understand the role of A9609 in PET imaging reimbursement and operational workflows at a national level.
Billing Code Overview
HCPCS Level II code A9609 describes fludeoxyglucose F18, up to 15 millicuries, a radiopharmaceutical dose commonly used in positron emission tomography (PET) imaging. This item represents the radiotracer supply component measured by activity (millicuries) and is typically billed when up to 15 mCi of Fludeoxyglucose F18 is provided for diagnostic imaging.
Service Type: Radiopharmaceutical supply for PET imaging
Typical Site of Service: Outpatient imaging centers, hospital outpatient departments, and freestanding PET facilities
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult referred for a positron emission tomography (PET) scan using Fludeoxyglucose F18 due to known or suspected malignancy, evaluation of metastatic disease, or assessment of treatment response. The patient presents to an outpatient imaging center or hospital radiology/nuclear medicine department after a history and physical exam by oncology, surgical, or primary care teams. Pre-procedure steps include verification of indication, review of blood glucose (ideally <200 mg/dL), fasting status (usually 4–6 hours), informed consent, and allergy and pregnancy screening. The radiopharmacy prepares and dispenses Fludeoxyglucose F18 in a dose up to 15 millicuries. The nuclear medicine technologist administers the radiotracer intravenously, observes an uptake interval (typically ~60 minutes), and positions the patient for PET/CT acquisition. The interpreting physician (nuclear medicine physician or radiologist) reviews images and issues a diagnostic report. Typical sites of service are outpatient imaging centers, hospital outpatient departments, and inpatient radiology suites when clinically indicated. Common clinical scenarios include initial staging of lung, colorectal, or head and neck cancers; restaging for suspected recurrence; evaluation of an indeterminate pulmonary nodule; and assessment of response to chemotherapy or immunotherapy.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 |